Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment

Vaccine

Volumn 34, Issue 39, 2016, Pages 4678-4683

  Guerra, Fiona M ^a   Rosella, Laura C ^a,b,c   Dunn, Sheila ^d,e   Wilson, Sarah E ^a,b,c   Chen, Cynthia ^a   Deeks, Shelley L ^a,b  

^a PUBLIC HEALTH ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Epidemiology; Genital warts; Health services research; HPV; Human papillomavirus; STI; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CONDYLOMA ACUMINATUM; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; ONTARIO; PAPANICOLAOU TEST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO; VACCINATION; YOUNG ADULT; PAPILLOMAVIRUS INFECTION; PREVENTIVE HEALTH SERVICE;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; LONGITUDINAL STUDIES; MALE; ONTARIO; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84991721582     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.020     Document Type: Article

References (31)

1. [1] Statistics Canada. Government of Canada, < http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm> [accessed February 4, 2016].
2. [2] Wilson, S.E., Karas, E., Crowcroft, N.S., Bontovics, E., Deeks, S.L., Ontario's school-based HPV immunization program: school board assent and parental consent. Can J Public Health/Rev Can Sante'e Publique, 2012, 34–39.
3. [3] Fairley, C.K., Hocking, J.S., Gurrin, L.C., Chen, M.Y., Donovan, B., Bradshaw, C.S., Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85:7 (2009), 499–502.
4. [4] Bauer, H.M., Wright, G., Chow, J., Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health 102:5 (2012), 833–835.
5. [5] Leval, A., Herweijer, E., Arnheim-Dahlström, L., Walum, H., Frans, E., Sparén, P., et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis, 2012, jis405.
6. [6] Leval, A., Herweijer, E., Ploner, A., Eloranta, S., Simard, J.F., Dillner, J., et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 105:7 (2013), 469–474.
7. [7] Ali, H., Guy, R.J., Wand, H., Read, T.R., Regan, D.G., Grulich, A.E., et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis, 13(1), 2013, 140.
8. [8] Ali, H., Donovan, B., Wand, H., Read, T.R., Regan, D.G., Grulich, A.E., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ, Brit Med J, 2013, 346.
9. [9] Baandrup, L., Blomberg, M., Dehlendorff, C., Sand, C., Andersen, K.K., Kjaer, S.K., Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 40:2 (2013), 130–135.
10. [10] Hariri, S., Markowitz, L.E., Dunne, E.F., Unger, E.R., Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 53:6 (2013), 679–682.
11. [11] Garland, S.M., The Australian experience with the human papillomavirus vaccine. Clin Ther 36:1 (2014), 17–23.
12. [12] Mariani, L., Vici, P., Suligoi, B., Checcucci-Lisi, G., Drury, R., Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Therapy 32:1 (2015), 10–30.
13. [13] Drolet, M., Bénard, É., Boily, M.C., Ali, H., Baandrup, L., Bauer, H., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15:5 (2015), 565–580.
14. [14] Camenga, D.R., Dunne, E.F., Desai, M.M., Gee, J., Markowitz, L.E., DeSiliva, A., et al. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis 40:7 (2013), 534–538.
15. [15] Steben, M., Ouhoummane, N., Rodier, C., Brassard, P., Temporal trends in genital warts among individuals covered by the public prescription drug insurance plan in the province of Quebec, Canada, from 1998 to 2007. J Lower Genital Tract Dis 17:2 (2013), 147–153.
16. [16] Guerra, F.M., Rosella, L.E., Dunn, S., Wilson, S.E., Chen, C., Deeks, S.L., Health service utilization for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine program introduction: a retrospective longitudinal population-based study. BMJ Open, 6(3), 2016, e009914.
17. [17] Marra, F., Ogilvie, G., Colley, L., Kliewer, E., Marra, C.A., Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 85:2 (2009), 111–115.
18. [18] Kliewer, E.V., Demers, A.A., Elliott, L., Lotocki, R., Butler, J.R., Brisson, M., Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 36:6 (2009), 380–386.
19. [19] Smith, L.M., Kaufman, J.S., Strumpf, E.C., Lévesque, L.E., Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario grade 8 HPV vaccine Cohort study. Can Med Assoc J 187:2 (2015), E74–E81.
20. [20] Lofters, A.K., Moineddin, R., Hwang, S.W., Glazier, R.H., Low rates of cervical cancer screening among urban immigrants: a population-based study in Ontario. Can Med Care 48:7 (2010), 611–618.
21. [21] Fairley, C.K., Donovan, B., What can surveillance of genital warts tell us?. Sex Health 7 (2010), 325–327.
22. [22] Ontario Agency for Health Protection and Promotion (Public Health Ontario), Immunization coverage report for school pupils: 2012–13 school year. 2014, Queen's Printer for Ontario, Toronto, ON.
23. [23] Canadian Immunization Committee. Recommendations on a human papillomavirus immunization program. Her Majesty the Queen in Right of Canada, represented by the Minister of Health; 2008. < http://www.phac-aspc.gc.ca/publicat/2008/papillomavirus-papillome/papillomavirus-papillome-index-eng.php>.
24. [24] Langille, D.B., Hughes, J.R., Delaney, M.E., Rigby, J.A., Older male sexual partner as a marker for sexual risk-taking in adolescent females in Nova Scotia. Can J Public Health/Rev Can Sante'e Publique 1 (2007), 86–90.
25. [25] Ford, K., Lepkowski, J.M., Characteristics of sexual partners and STD infection among American adolescents. Int J STD AIDS 15:4 (2004), 260–265.
26. [26] Millar, W.J., Wadhera, S., A perspective on Canadian teenage births, 1992–94: older men and younger women?. Can J Public Health/Rev Can Sante Publique 88:5 (1996), 333–336 Dec.
27. [27] National Advisory Committee on Immunization (NACI), Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 33:ACS-2 (2007), 1–31.
28. [28] Smith, L.M., Strumpf, E.C., Kaufman, J.S., Lofters, A., Schwandt, M., Lévesque, L.E., The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics 135:5 (2015), e1131–e1140.
29. [29] Rotermann, M., Trends in teen sexual behaviour and condom use. Health Rep 19:3 (2008 Sep 1), 53–57.
30. [30] Bednarczyk, R.A., Davis, R., Ault, K., Orenstein, W., Omer, S.B., Sexual activity–related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics 130:5 (2012), 798–805.
31. [31] Tanday, S., HPV vaccinations do not encourage risky sexual behaviour. Lancet Oncol, 15(3), 2014, e109.